|
1
|
Dimenäs E: Methodological aspects of
evaluation of Quality of Life in upper gastrointestinal diseases.
Scand J Gastroenterol Suppl. 199:18–21. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Iwakiri K, Kinoshita Y, Habu Y, Oshima T,
Manabe N, Fujiwara Y, Nagahara A, Kawamura O, Iwakiri R, Ozawa S,
et al: Evidence-based clinical practice guidelines for
gastroesophageal reflux disease 2015. J Gastroenterol. 51:751–767.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Suzuki H, Matsuzaki J, Okada S, Hirata K,
Fukuhara S and Hibi T: Validation of the GerdQ questionnaire for
the management of gastro-oesophageal reflux disease in Japan.
United European Gastroenterol J. 1:175–183. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Toghanian S, Johnson DA, Stålhammar NO and
Zerbib F: Burden of gastro-oesophageal reflux disease in patients
with persistent and intense symptoms despite proton pump inhibitor
therapy: A post hoc analysis of the 2007 national health and
wellness survey. Clin Drug Investig. 31:703–715. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sakurai Y, Mori Y, Okamoto H, Nishimura A,
Komura E, Araki T and Shiramoto M: Acid-inhibitory effects of
vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10
mg in healthy adult male subjects-a randomised open-label
cross-over study. Aliment Pharmacol Ther. 42:719–730. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shinozaki S, Nomoto H, Kondo Y, Sakamoto
H, Hayashi Y, Yamamoto H, Lefor AK and Osawa H: Comparison of
vonoprazan and proton pump inhibitors for eradication of
Helicobacter pylori. Kaohsiung J Med Sci. 32:255–260. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hoshino S, Kawami N, Takenouchi N, Umezawa
M, Hanada Y, Hoshikawa Y, Kawagoe T, Sano H, Hoshihara Y, Nomura T,
et al: Efficacy of vonoprazan for proton pump inhibitor-resistant
reflux esophagitis. Digestion. 95:156–161. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kakuta E, Yamashita N, Katsube T,
Kushiyama Y, Suetsugu H, Furuta K and Kinoshita Y: Abdominal
symptom-related QOL in individuals visiting an outpatient clinic
and those attending an annual health check. Intern Med.
50:1517–1522. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kimura K and Takemoto T: An endoscopic
recognition of the atrophic border and its significance in chronic
gastritis. Endoscopy. 1:87–97. 1969. View Article : Google Scholar
|
|
10
|
Shinozaki S, Osawa H, Sakamoto H, Hayashi
Y, Lefor A Kawarai and Yamamoto H: The effect of acotiamide on
epigastric pain syndrome and postprandial distress syndrome in
patients with functional dyspepsia. J Med Invest. 63:230–235. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yoshioka T, Okimoto N, Okamoto K and Sakai
A: A comparative study of the effects of daily minodronate and
weekly alendronate on upper gastrointestinal symptoms, bone
resorption, and back pain in postmenopausal osteoporosis patients.
J Bone Miner Metab. 31:153–160. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Okimoto E, Ishimura N, Morito Y, Mikami H,
Shimura S, Uno G, Tamagawa Y, Aimi M, Oshima N, Kawashima K, et al:
Prevalence of gastroesophageal reflux disease in children, adults,
and elderly in the same community. J Gastroenterol Hepatol.
30:1140–1146. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kinoshita Y and Chiba T: FUTURE study
group: Therapeutic effects of famotidine on chronic symptomatic
gastritis: Subgroup analysis from FUTURE study. J Gastroenterol.
47:377–386. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kinoshita Y and Chiba T: FUTURE study
group: Characteristics of Japanese patients with chronic gastritis
and comparison with functional dyspepsia defined by ROME III
criteria: Based on the large-scale survey, FUTURE study. Intern
Med. 50:2269–2276. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tack J and Fass R: Review article:
approaches to endoscopic-negative reflux disease: part of the GERD
spectrum or a unique acid-related disorder? Aliment Pharmacol Ther
19. Suppl 1:28–34. 2004. View Article : Google Scholar
|
|
16
|
Kagami T, Sahara S, Ichikawa H, Uotani T,
Yamade M, Sugimoto M, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, et
al: Potent acid inhibition by vonoprazan in comparison with
esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol
Ther. 43:1048–1059. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kinoshita Y and Hongo M: Japan TWICE study
group: Efficacy of twice-daily rabeprazole for reflux esophagitis
patients refractory to standard once-daily administration of PPI:
The Japan-based TWICE study. Am J Gastroenterol. 107:522–530. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kinoshita Y, Hongo M, Kusano M, Furuhata
Y, Miyagishi H and Ikeuchi S: RPZ Study Group: Therapeutic response
to twice-daily Rabeprazole on health-related quality of life and
symptoms in patients with refractory reflux esophagitis: A
multicenter observational study. Intern Med. 56:1131–1139. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fackler WK, Ours TM, Vaezi MF and Richter
JE: Long-term effect of H2RA therapy on nocturnal gastric acid
breakthrough. Gastroenterology. 122:625–632. 2002. View Article : Google Scholar : PubMed/NCBI
|
